ASX-listed clinical-stage biotechnology group Cynata Therapeutics is on the brink of notching up yet another patent for its proprietary Cymerus mesenchymal stem cells technology. The company says it has now received notification from the Patent Office of the Russian Federation confirming Cynata’s patent applications have been accepted and that the patent body intends granting two new patents in relation to the technology.
Melbourne-based Cynata’s new Russian patents, which are expected to come through later this year and due to expire in 2037, follow hot on the heels of its recent patent application successes in the United States and in Canada.
The patent recognition of the Cymerus biotechnology delivers a “substantial” intellectual property asset base in markets of major commercial importance, according to the company.
Cynata continues to build meaningful value in its Cymerus stem cell technology platform through the advancement of its unique and proprietary intellectual property portfolio. The Cymerus platform enables manufacture of consistent, high-quality mesenchymal stem cells at scale. This unique and valuable characteristic of Cynata’s technology is key to the development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide.
Management says these further Cynata patents continue to build on the broad intellectual property protection of Cynata’s manufacturing platform and its unique ability to yield highly consistent mesenchymal stem cells at scale, from a single donation, to create therapeutic stem cell products.
Cynata unveiled late last month that it had been issued with a “notice of allowance” from both the Canadian Intellectual Property Office and the US Patent and Trademark Office for its patent applications pertaining to Cymerus.
The $80 million market-capped clinical-stage stem cell and regenerative medicine company anticipates the US patent being granted in November this year and the Canadian patent early next year.
Cynata says the milestone patents help de-risk the commercialisation potential of the Cymerus therapeutic stem cell platform technology.
Cymerus mesenchymal stem cells have been previously portrayed by Cynata as the “conductor of the orchestra in the body”.
The company says they have not only been demonstrated to be effective and safe against several diseases in pre-clinical rodent studies but also in current clinical trials for diseases including osteoarthritis and respiratory failure.
Planning is also under way for further clinical testing of the impacts of Cymerus mesenchymal stem cells on patients with the lung disease idiopathic pulmonary fibrosis and diabetic foot ulcers.
Is your ASX-listed company doing something interesting? Contact: firstname.lastname@example.org